Pages that link to "Q41658924"
Jump to navigation
Jump to search
The following pages link to Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features (Q41658924):
Displaying 22 items.
- Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. (Q31109447) (← links)
- Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach (Q33740717) (← links)
- A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy (Q36092829) (← links)
- Surgical challenges in the treatment of a giant renal cell carcinoma with atypical presentation: A case report (Q36918877) (← links)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (Q37414808) (← links)
- A Three-Variable Model Predicts Short Survival in Patients With Newly Diagnosed Metastatic Renal Cell Carcinoma (Q37672155) (← links)
- Renal Cell Carcinoma Update: News from the AUA, EAU, and ASCO Annual Meetings 2011. (Q38025115) (← links)
- The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies (Q38094592) (← links)
- Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review (Q38681585) (← links)
- Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma (Q40908884) (← links)
- Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. (Q47207045) (← links)
- Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy (Q47898943) (← links)
- Role of cytoreductive nephrectomy in the targeted therapy era: A systematic review and meta-analysis. (Q48246088) (← links)
- Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: A 16-year retrospective analysis (Q50217752) (← links)
- Minimally invasive cytoreductive nephrectomy: a multi-institutional experience (Q50665147) (← links)
- Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale? (Q50791794) (← links)
- Predictive value of inflammation-based prognostic scores in patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy. (Q55339581) (← links)
- Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy (Q57466362) (← links)
- Collecting duct carcinoma of the kidney: Disease characteristics and treatment outcomes from the National Cancer Database (Q88042885) (← links)
- Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift? (Q90811565) (← links)
- The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma (Q91632505) (← links)
- Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors (Q96811984) (← links)